Bank of America reaffirmed their underperform rating on shares of Lucira Health (NASDAQ:LHDX) in a research report report published on Monday, Benzinga reports. They currently have a $9.00 price target on the stock.
LHDX has been the subject of several other reports. William Blair initiated coverage on shares of Lucira Health in a research report on Monday, March 8th. They set an outperform rating for the company. Lifesci Capital restated an outperform rating on shares of Lucira Health in a report on Tuesday, March 2nd.
NASDAQ:LHDX opened at $7.10 on Monday. The stock’s 50-day simple moving average is $11.79. Lucira Health has a one year low of $6.66 and a one year high of $37.99.
Lucira Health Company Profile
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops testing platform that provides molecular testing services. The company offers LUCIRA COVID- 19 All- In- One Test Kit, that provides COVID- 19 result; and develops influenza A and B viruses test kits.
Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.